Indicated for: prostate cancer; breast cancer; endometriosis
Route of administration: implantation
Substance: leuprorelin (GnRH agonist)
ATC: L02AE02 (Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues)
Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of prostate cancer, endometriosis, and precocious puberty. It works by suppressing the production of sex hormones, thereby reducing disease progression.
The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.
Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.
Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.